Keros Therapeutics

IPO

Powered by TGF-ß science, inspired by patients

Public · Lexington, United States · Founded 2015 · $97.0M raised

Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$97.0M
Last Round
$56.0M Series CJan 2020
Rounds
3
Type
Public

About

Keros Therapeutics develops and commercializes novel therapeutics that modulate transforming growth factor-beta (TGF-β) signaling for patients with disorders linked to dysfunctional TGF-β family proteins. The TGF-β superfamily is a group of regulatory proteins key to the growth, repair, and maintenance of blood cells and a number of tissues. Leveraging this science, Keros focuses on potentially disease-modifying therapies in hematology and neuromuscular disease, including product candidates KER-050 and KER-065.

Summary

Keros Therapeutics is a Biotech company based in Lexington, United States, founded in 2015. It has raised $97.0M in total across 3 rounds, most recently a $56.0M Series C round in Jan 2020. Investors include OrbiMed and Foresite Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJan 2020
$96.0M

Sign up to see all 4 rounds

Series A through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Keros Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/keros-therapeutics"><img src="https://indexed.vc/api/badge/company/keros-therapeutics" alt="Keros Therapeutics on Indexed.vc" width="260" height="76" /></a>